Trelegy Indication
Trelegy (fluticasone furoate/umeclidinium/vilanterol) is FDA-approved for two indications: (1) maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults, and (2) maintenance treatment of asthma in patients aged 18 years and older. 1
Primary Indications
COPD Maintenance Treatment
Trelegy is indicated for the maintenance treatment of patients with COPD 1. The 2023 Canadian Thoracic Society guidelines support single-inhaler triple therapy (SITT) in:
- Patients with persistent moderate to severe dyspnea and/or poor health status despite treatment with dual therapy (LAMA/LABA or ICS/LABA) 2
- All patients at high risk of COPD exacerbations, given that SITT reduces mortality in individuals with moderate-severe disease and high exacerbation risk 2
The standard COPD dosing is one actuation of 100/62.5/25 mcg once daily 1.
Asthma Maintenance Treatment
Trelegy is indicated for maintenance treatment of asthma in adults aged 18 years and older 1. For asthma, two dosing options are available:
- 100/62.5/25 mcg once daily, or
- 200/62.5/25 mcg once daily 1
Critical Limitations of Use
Trelegy is NOT indicated for relief of acute bronchospasm 1. This is a crucial safety consideration—patients must understand this is a maintenance medication only.
Contraindications
Trelegy is contraindicated in:
- Primary treatment of status asthmaticus or acute episodes of COPD or asthma requiring intensive measures 1
- Severe hypersensitivity to milk proteins or any ingredients 1
Clinical Context from Guidelines
The 2023 CTS guidelines emphasize that triple therapy represents a paradigm shift in COPD management, where treatment goals now include not only alleviating symptoms and preventing exacerbations, but also reducing mortality 2. This mortality benefit is particularly important for patients with moderate-severe COPD at high risk of exacerbations.
Real-world evidence demonstrates that Trelegy is used appropriately in clinical practice, with 92% of French patients having received dual or triple therapy prior to initiation 3, and the medication showing effectiveness in reducing exacerbations and improving health status in symptomatic COPD patients 4.
Common Pitfalls to Avoid
- Do not prescribe for acute symptom relief—patients need a separate rescue inhaler
- Do not combine with additional LABA-containing medications due to overdose risk 1
- Do not initiate during acute deterioration of COPD or asthma 1
- Screen for milk protein allergy before prescribing, as this is an absolute contraindication 1